But the serial acquirers that defined the last decade of
specialty pharma dealmaking — Teva Pharmaceuticals, Valeant Pharmaceuticals, and Endo International — are no longer in the position to take on bigger deals, as they're all saddled with too much debt.
A tie - up between Takeda and Shire could signal a new era for
specialty pharma dealmaking, say analysts and investors, as interest in the sector intensifies again.
Not exact matches
The
specialty pharma industry has historically been an area filled with
dealmaking but has been more subdued over the past few years.